Parametric Portfolio Associates’s Xenon Pharmaceuticals XENE Stock Holding History

Parametric Portfolio Associates’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$805K	Buy	+26,338	New	+$788K	﹤0.01%	2879

Other funds holding XENE

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Parametric Portfolio Associates's XENE Position: Q1 2022 in Review

Parametric Portfolio Associates opened a new position in Xenon Pharmaceuticals (XENE) in Q1 2022: 26,338 shares worth $805K. The stake represents ﹤0.01% of the portfolio and ranks #2879 among its holdings.

134 funds tracked by Wall St. Rank hold XENE as of Q1 2022.

Parametric Portfolio Associates held 26,338 shares of Xenon Pharmaceuticals worth $805K as of Q1 2022.
Xenon Pharmaceuticals was a new Parametric Portfolio Associates position in Q1 2022.
Xenon Pharmaceuticals made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2879 holding.
134 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.